Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033125 | 0.84 | ESRRG (0.45) | SIGMAR1 | |
| SCHEMBL13225831 | 0.82 | FFAR1 (0.56) | FFAR1FFAR4LTA4HEPHX2ALOX5 | |
| SCHEMBL947617 | 0.79 | S1PR1 (0.72) | FFAR1S1PR1S1PR3LTA4HS1PR5 | |
| SCHEMBL4026294 | 0.79 | PPARG (0.57) | — | |
| SCHEMBL5947113 | 0.79 | FFAR1 (0.66) | FFAR1FFAR4 | |
| SCHEMBL15096997 | 0.78 | MAPT (0.57) | FFAR1S1PR1S1PR3S1PR5 | |
| SCHEMBL4032522 | 0.78 | PPARG (0.44) | S1PR1S1PR3S1PR5 | |
| SCHEMBL7275476 | 0.77 | BCHE (0.56) | BCHEFFAR1FFAR4SIGMAR1LTA4H | |
| SCHEMBL7874020 | 0.76 | MEN1 (0.58) | FFAR1FFAR4LTA4HALOX5 | |
| SCHEMBL7869987 | 0.75 | LMNA (0.57) | FFAR1FFAR4LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20090275565-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | BCHE 3313/4885FFAR1 2147/4885FFAR4 2294/4885 |
| US-20090275565-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | BCHE 3313/4885FFAR1 2147/4885FFAR4 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.